Logo for Agios Pharmaceuticals Inc

Agios Pharmaceuticals Investor Relations Material

Latest events

Logo for Agios Pharmaceuticals Inc

Q4 2023

Agios Pharmaceuticals
Logo for Agios Pharmaceuticals

Q4 2023

15 Feb, 2024
Logo for Agios Pharmaceuticals

Study Result

11 Dec, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Agios Pharmaceuticals Inc

Access all reports
Agios Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company's lead product candidate for metabolic diseases is AG-126, which is in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis. Agios is also developing novel orally available drugs to improve statin responses in patients with hypercholesterolemia and mixed dyslipidemia. The company has collaborations with Amgen Inc., Boehringer Ingelheim, GlaxoSmithKline Plc, Roche Holding AG, Sanofi SA, and Pfizer Inc.; and Abbott Laboratories. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.